TY - JOUR
T1 - Inhaled atropine sulfate. Dose-response characteristics in adult patients with chronic airflow obstruction
AU - Pak, C. C.F.
AU - Kradjan, W. A.
AU - Lakshminarayan, S.
AU - Marini, J. J.
PY - 1982/1/1
Y1 - 1982/1/1
N2 - Dose-response characteristics of inhaled atropine sulfate were examined in ten patients with chronic airflow obstruction using spirometric and plethysmographic measurements. Inhaled atropine in doses of 0.005, 0.01, 0.025, and 0.05 mg/kg of body weight and placebo were delivered by means of a precision metering device. All pulmonary function tests (FEV1, V̇50, and SGaw) improved progressively with increasing dose. There was a high degree of linear correlation between the peak response of each test and the logarithm of dose (r ≥ 0.98). The highest dose studied (0.05 mg/kg) was found to have marginal benefit over 0.025 mg/kg, and had the highest incidence of adverse reactions. Duration of effect was dependent on dose. These results suggest that for adult patients with chronic obstruction, 0.025 mg/kg delivered by a dosimeter approximates the optimally effective dose of inhaled atropine sulfate that can be given without unacceptable side effects.
AB - Dose-response characteristics of inhaled atropine sulfate were examined in ten patients with chronic airflow obstruction using spirometric and plethysmographic measurements. Inhaled atropine in doses of 0.005, 0.01, 0.025, and 0.05 mg/kg of body weight and placebo were delivered by means of a precision metering device. All pulmonary function tests (FEV1, V̇50, and SGaw) improved progressively with increasing dose. There was a high degree of linear correlation between the peak response of each test and the logarithm of dose (r ≥ 0.98). The highest dose studied (0.05 mg/kg) was found to have marginal benefit over 0.025 mg/kg, and had the highest incidence of adverse reactions. Duration of effect was dependent on dose. These results suggest that for adult patients with chronic obstruction, 0.025 mg/kg delivered by a dosimeter approximates the optimally effective dose of inhaled atropine sulfate that can be given without unacceptable side effects.
UR - http://www.scopus.com/inward/record.url?scp=0020077591&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0020077591&partnerID=8YFLogxK
M3 - Article
C2 - 7039438
AN - SCOPUS:0020077591
VL - 125
SP - 331
EP - 334
JO - American Journal of Respiratory and Critical Care Medicine
JF - American Journal of Respiratory and Critical Care Medicine
SN - 1073-449X
IS - 3 I
ER -